January #67 : Cardio Calculus - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Here Comes the Cure

Magical Mystery Cure

Cancer Rising

One To Watch: Frank Oldham

Opposite of Sex

Are the Kids Alright?

Paint by Numbers

Withdrawal Symptoms

Say What?

Safe-Surf Guidelines

The Down-Low Lowdown

You Can't Go Home Again

Teach Your Children Well

Personal Transformations

Lost in Disk Space

Buenas Noches

No Intermission

Tribute: Jacqueline M. Fuentes


Cardio Calculus

Herb Of The Month: Green Tea

When Chemo Calls


Kiss Lipo BUH-BYE?

Tonic for Two

Nukelier Fusion

Peppier Paps

Comfort Zone

On the Brink of Ink

Cyber Rx

Love's Labor

Heartbreak Hotel

Editor's Letter


01.01.93 Defining Moment

The Baby Blues

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

January 2001

Cardio Calculus

by Lark Lands

HAART or heart disease? Plug your numbers into this fancy formula, grind a crank, and the answer flies out all over the chalkboard.

Their eyes didn't actually shoot out of their sockets on springs -- boinggg!!! -- but there was a certain cartoonishness in how the audience snapped to attention when Swiss epidemiologist Matthias Egger, MD, presented his mathematical baby at the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV in Toronto last September. Oddly, Egger's formula for comparing the likely benefits of HAART (Number Needed to Treat to Benefit, or NNTb) with the potential risk for cardiac disease (Number Needed to Treat to Harm, or NNTh) would have elicited little more than a yawn from public health experts for whom the comparison is second nature, but to HIV researchers it was an eye-opener.

At a time when many HIVers are weighing the risk of HAART-caused heart disease against the consequences of delaying -- or stopping -- combo therapy, this calculation could offer a rational basis for making the heart-stopping big decision. Plus, it might help tell you not only when to start treatment but, where cardiac effects are known, which drugs to use. Comparing U.S. research on the pre-HAART risk of disease progression with Swiss data on the rate among HAARTers, the Eggerhead first showed that the pills produce an 86 percent reduction in AIDS progression among those with high viral loads (greater than 110,000) and low CD4 counts (under 200), but only a 2 percent reduction among those with low viral loads (3,000-14,000) and higher CD4 counts (200-350). To put some fat on these stats, he then calculated the number of HIVers who would need to be treated for one additional person to benefit. For those with advanced HIV, the ability of HAART to slow disease progression is so great that the NNTb was only one or two people, but for those with better counts, it was 50.

The good Egger then cracked the NNTh code. By adding Australian data on the cardiac risk factors that lipodystrophy sufferers face (increased total cholesterol or triglycerides, decreased HDL cholesterol, high blood pressure, insulin resistance or diabetes) to other risk factors (age, gender, smoking), he showed that for some HIVers, the potential for harm from HAART may outweigh its good. A no-brainer example: An aging two-pack-a-dayer, say, with a 3,000 viral load and 450 CD4s. But with seemingly endless combos of risk factors for both HIV and cardiac disease progression, a plug-in-your-info formula to weigh NNTb vs. NNTh could be as handy as an egg-timer. The magic formula for HIVers is still in the works, but at www.hbroussais.fr/Scientific/fram.eng.html you can calculate your cardio risk (a command of French helps).

Egger's brainchild, together with other findings from studies reported here from the lipo workshop and the major-league Interscience Conference on Antimicrobials and Chemotherapy that followed, mark a great leap from past years' woolly theorizing to tools that may help you take heart about taking HAART (or not).

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.